Abstract
Cancer is the second most common cause of death in the industrialized world.
At this time, treatment for cancer focuses on some combination of surgery,
radiation, and chemotherapy.
But over the next five years, treatment is going to dramatically change. as
detailed in the report Monoclonal Antibodies, Vaccines and Other Immunologic
Cancer Treatments: World Market from Kalorama Information. One of the most
promising new approaches in modern cancer treatment is immunotherapy, the
development of methods to augment and enhance the body' s natural tendency to
defend itself against malignant tumors without damaging healthy tissue.
Immunological and biotherapy treatments which target therapy are a fraction of
total cancer treatment revenues at the current time, but will soon make up the
lion' s share of the total cancer therapy market. The novel treatments covered
in this report includes:
- Monoclonal Antibodies cloned antibody molecules produced by
specialized tissue cell culture lines, that specifically bind with target
antigens and could therefore be used in several ways to treat cancer.
Antibodies can be used to deliver a cytotoxic drug preferentially to the
cancer cell and thus minimize drug interactions with normal cells.
- Vaccines that can develop resistance to cancer in populations.
Already, vaccines that deal with pre-cancer infections such as Gardasil and
soon-to be-released Cerevix are attracting attention. More therapeutic
vaccines are in Phase III trial at this time.
- To a more limited extent, Interleukins and Interferons are utilized
and their use and market potential is described in the report.
- Other Biotherapy including treatments such as treatments such as;
antisense oligonucleotides, apoptosis, or programmed cell death, protein and
polypeptide growth factors, methylation, p53 tumor suppressor proteins, ras
proteins, regulatory enzymes and other therapies.
Clearly immunologic treatments have moved beyond theory and Kalorama
Information takes this growing sector and establishes a clear market picture.
This global report details:
- Market Share for companies in this area.
- Company Profiles of key competitors and their Current Products.
- Global Data: US, Europe, Japan and Rest of World revenues and
forecasts.
- Forecasts to 2011 for sales of Monoclonal Antibodies, Vaccines and
other biotherapeutic treatment segments.
- Extensive Review of New Product Pipeline.
Product managers, Marketing executives, Advertising and financial executives
are among those who will find this information on these novel cancer
treatments essential.
Table of Contents
Chapter One: Executive Summary
- Overview
- Market Size and Growth
- Markets by Geographical Segments
- U.S. Market
- European Market
- Japanese Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
- Scope and Methodology
Chapter Two: Introduction
- Overview
- Monoclonal Antibodies
- Interleukins/Interferons
- Vaccines
- Other Biotherapy
- Antisense Oligonucleotides
- Apoptosis
- Growth Factors
- Methylation
- P53
- Ras Protein Drugs
- Regulatory Enzymes
- Description of Products
- Monoclonal Antibodies
- Avastin (bevacizumab)
- Campath (alemtuzumab)
- Erbitux (cetuximab)
- Herceptin (trastuzumab)
- Mylotarg (gemtuzumab ozogamicin)
- Panorex (edrecolomab)
- Rituxan (rituximab)
- Interleukins/Interferons
- Alferon-N
- Infergen
- Intron A
- Proleukin
- Roferon A
- Vaccines
- Gardasil
- M-Vax
- Melacine
- OncoTICE
- OncoVax
- Pacis
- TheraCys (ImmuCyst)
- Other Biotherapy
- Enzyme Adenosine Deaminase
- Tyrosine Kinases
- Proteasome Inhibitors
- Newly Approved Immunotherapy Drugs
Chapter Three: Research and Development
- Pipeline For BioTherapeutic/Immunologic Treatments
- Avastin
- Cervarix
- Dimericine
- Genta
- Junovan
- Tykerb
- M-Vax
- Panitumumab
- Provenge
- Tasigna
- Atrasentan (Xinlay)
- Rituxan
- Advexin
- Allovectin-7
- Alvocidib
- Insegia
- Affinitak
- AMG 162
- Anti-gastrin Immunogen G17DT
- Avicine
- BAY 43-9006 (Nexavar)
- Biovaxid
- Ceplene
- Cintredekin
- Cloretazine
- CoFactor (ANX-510)
- Cotara
- DCVax
- Enzastaurin
- Erbitux
- FavId
- Glufosfamide
- GMK vaccine
- G-Top 99 / MyVax Personalized Immunotherapy
- GVAX vaccine for prostate cancer
- HuMax-CD4 (zanolimumab)
- Ipilimumab
- Iressa
- Ixabepilone
- Javlor
- Neovastat
- Onconase
- Oncophage
- OncoVAX
- OvaRex
- PANVAC-VF
- PEG-Intron
- PF-3512676
- Phenoxodiol
- PTK787/ZK 222584
- Rencarex
- Romidepsin
- Tarceva (erlotinib)
- Telcyta A GST P1-1
- Temsirolimus
- Tesmilifene
- Thymitaq
- TransMID
- Urocidin
- Virulizin
- Xcytrin
- XL119
- Yondelis
- Zactima
- Stimuvax
Chapter Four: Market Data
- Market Size and Growth
- Markets by Product Type
- Markets by Geographical Segments
- U.S. Market
- European Market
- Japanese Market
- ROW Market
- Market Data by Indication
- Competitive Analysis
Chapter Five: Corporate Profiles
- Introduction
- Amgen, Inc
- Biogen IDEC, Inc
- Bristol-Myers Squibb Company/Oncology
- Genentech, Inc
- GlaxoSmithKline plc
- Merck & Company, Inc.
- Novartis Pharmaceuticals Corporation/Oncology
- Roche
- Sanofi-Aventis
- TAP Pharmaceutical Products, Inc.
Table of Exhibits
Chapter One: Executive Summary
- Figure 1-1: Immunological and Biotherapy Treatments as Percentage of Total
Cancer Treatment Market, 2006 and 2011
- Figure 1-2: World Cancer Immunotherapy Market, 2006 2011
- Figure 1-3: World Cancer Immunotherapy Market Estimated Products Sales by
Region, 2006
- Figure 1-4: World Cancer Immunotherapy Market Estimated Products Sales by
Cancer Type, 2006
Chapter Two: Introduction
- Table 2-1: Monoclonal Antibodies
- Table 2-2: Interleukin/Interferon
- Table 2-3: Vaccines
- Table 2-4: Other Biotherapy
- Table 2-5: Newly Approved Immunotherapy/Biologic Agents
Chapter Three: Research and Development
- Table 3-1:Cancer Immunotherapy and Biotherapy Products in Late Stage
Development (Product, Developer, Current Phase, Cancer Type, and Earliest
Approval Date)
Chapter Four: Market Data
- Table 4-1: World Cancer Immunotherapy Market, 2004-2011 (in millions of
dollars at the manufacturers level)
- Figure 4-1: World Cancer Immunotherapy Market, 2004-2011 (in millions of
dollars at the manufacturers level)
- Table 4-2: World Cancer Immunotherapy Market; Market by Product Type
(Monoclonal Antibodies, Interleukins/Interferons, Vaccines and Other
Biotherapy), 2004-2011
- Figure 4-2: World Cancer Immunotherapy Market Market by Product Type
Revenues, 2004-2011 (in millions at the manufacturers level)
- Figure 4-3: World Cancer Immunotherapy Market Market by Product Type and
Percent Distribution, 2004-2011
- Figure 4-4: World Cancer Immunotherapy Market Market by Product Type and
Percent Market Share, 2006
- Figure 4-5: World Cancer Immunotherapy Market Market by Product Type and
Percent Market Share, 2011
- Table 4-3: World Cancer Immunotherapy Market Estimated Products Sales by
Region (U.S., Europe, Japan, Rest of World), 2004-2011 (in million of dollars
at the manufacturers level) Estimated Revenues
- Figure 4-6: World Cancer Immunotherapy Market Estimated Product Sales by
Region, 2004-2011 (in millions at the manufacturers level)
- Figure 4-7: World Cancer Immunotherapy Market Estimated Products Sales by
Region, 2006
- Figure 4-8: World Cancer Immunotherapy Market Estimated Products Sales by
Region, 2011
- Table 4-4: World Cancer Immunotherapy Market Estimated Products Sales by
Cancer Type, 2006 (in million of dollars at the manufacturers level)
- Figure 4-9: World Cancer Immunotherapy Market Estimated Products Sales by
Cancer Type, 2006
- Table 4-5: World Cancer Immunotherapy Market Leading Suppliers Shares by
Market Revenues, Estimated 2006 and Projected 2011 (in million of dollars at
the manufacturers level)
- Figure 4-10: World Cancer Immunotherapy Market Leading Suppliers Market
Share, Estimated 2006
- Figure 4-11: World Cancer Immunotherapy Market Leading Suppliers Market
Share, Projected 2011
- Table 4-6: World Cancer Immunotherapy Market Top Cancer Immunotherapy
Products by Estimated Sales and Percent of Market, 2006 (in million of dollars
at the manufacturers level)
- Figure 4-12: World Cancer Immunotherapy Market Top Cancer Immunotherapy
Products by Estimated Sales and Percent of Market, 2006
Chapter Five: Corporate Profiles
|
相關報告
|
